What Is Bioidentical Hormone Therapy for Men?

Bioidentical Hormones: The Core Definition

Bioidentical hormones are compounds whose molecular structure is an exact match to hormones the human body synthesizes on its own. For men, the target hormone is almost always testosterone, though clinicians may also address DHEA, progesterone, or thyroid hormones when appropriate. The word "bioidentical" describes molecular geometry, not origin. Both FDA-approved products and compounded preparations can be bioidentical.

This distinction matters because marketing frequently conflates "bioidentical" with "natural" or "safer." The FDA does not recognize "bioidentical" as a regulatory category. What determines safety and efficacy is the evidence base behind a specific product and formulation, not the label.

How Bioidentical Differs from Synthetic

Traditional synthetic androgens, such as methyltestosterone (no longer widely used) or nandrolone, have altered ring structures compared to endogenous testosterone. Those alterations change how the molecule binds to receptors, how it is metabolized, and what side-effect profile it carries. Methyltestosterone, for instance, is 17-alpha alkylated, which makes it orally bioavailable but hepatotoxic. Bioidentical testosterone cypionate is esterified at the 17-beta hydroxyl position, allowing depot release without liver toxicity, and its active metabolite is the same testosterone the testes would produce.

The Role of Compounding Pharmacies

Compounding pharmacies prepare custom formulations, such as testosterone creams at non-standard concentrations, sublingual troches, or pellets dosed to a specific patient's needs. These products contain bioidentical molecules. They are not, however, FDA-approved as finished drug products, because they have not undergone the same large-scale clinical trials required for approval. The FDA has raised concerns about the safety claims made for compounded BHRT and has issued guidance noting that compounded preparations are not proven safer or more effective than FDA-approved alternatives. [1]

Why Men Seek Bioidentical Hormone Therapy

Low testosterone (hypogonadism) affects an estimated 2-4% of men overall, with prevalence rising sharply after age 45. [2] Symptoms drive most consultations.

Classic Symptoms of Low Testosterone

• Persistent fatigue and reduced stamina
• Decreased libido and erectile difficulty
• Loss of lean muscle mass with increased body fat
• Cognitive fog and low mood
• Reduced bone mineral density
• Decreased morning erections

The Endocrine Society's 2018 Clinical Practice Guideline defines biochemical hypogonadism as a total serum testosterone below 300 ng/dL confirmed on two separate morning samples, drawn between 7 and 10 AM. [3] Symptoms alone are insufficient for diagnosis. Both biochemical confirmation and clinical symptoms are required before treatment is initiated.

Who Qualifies Clinically

Men with primary hypogonadism (testicular failure), secondary hypogonadism (pituitary-hypothalamic dysfunction), or late-onset hypogonadism (age-related decline) may qualify. Men who are actively trying to conceive are generally not candidates for exogenous testosterone, because suppression of LH and FSH reduces intratesticular testosterone and impairs spermatogenesis. Alternatives like clomiphene citrate or hCG are used instead in that population.

FDA-Approved Bioidentical Testosterone Products

Every testosterone molecule in the approved products below is structurally identical to endogenous testosterone. The differences lie in ester, carrier, and delivery route.

Injectable Formulations

Testosterone cypionate (Depo-Testosterone) and testosterone enanthate are the most prescribed forms in the United States. Cypionate is typically dosed at 100-200 mg intramuscularly every 7-14 days, though subcutaneous administration at 50-100 mg weekly produces more stable serum levels and is increasingly preferred. Enanthate behaves almost identically, with a half-life of roughly 4.5 days versus cypionate's 8 days.

Testosterone undecanoate (Aveed), approved in 2014, is dosed at 750 mg IM at weeks 0 and 4, then every 10 weeks. [4] Its longer half-life reduces injection frequency but requires a 30-minute post-injection observation period in a certified healthcare setting due to a small risk of pulmonary oil microembolism.

Topical Gels and Creams

AndroGel (1% and 1.62%), Testim (1%), Vogelxo (1%), and Fortesta (2%) are FDA-approved testosterone gels applied daily to shoulders, upper arms, or inner thighs. Absorption varies. Transfer to female partners or children through skin contact is a real risk that requires strict hygiene practices. [5]

Nasal Gel

Natesto delivers 11 mg of testosterone intranasally three times daily. Unlike transdermal products, it does not suppress LH and FSH as profoundly, making it a potential option for men who want to preserve fertility. A 2016 study (N=316) showed that 74% of Natesto users maintained sperm concentrations above 15 million/mL after 6 months. [6]

Oral Capsule

Testosterone undecanoate (Jatenzo, Tlando, Kyzatrex) is the first oral testosterone approved in decades. Jatenzo was approved by the FDA in 2019. [7] These capsules use a lymphatic absorption pathway, bypassing first-pass hepatic metabolism. Doses range from 158-396 mg twice daily with food.

Transdermal Patch

Androderm patches (2 mg/day and 4 mg/day) are applied nightly to the back, abdomen, upper arm, or thigh. Skin irritation at the patch site occurs in approximately 37% of users, which limits adherence.

Compounded Bioidentical Options

The table below outlines the major compounded BHRT delivery methods for men, their approximate dosing ranges, and key clinical trade-offs. This framework was developed by the HealthRX medical team to standardize patient counseling.

| Formulation | Typical Dose Range | Frequency | Key Trade-off | |---|---|---|---| | Testosterone cream (10-20%) | 50-200 mg | Daily | High inter-patient absorption variability | | Subcutaneous pellet | 100-200 mg per pellet, 4-10 pellets | Every 3-6 months | Cannot adjust dose once inserted | | Sublingual troche | 25-50 mg | Once or twice daily | Significant swallowing of saliva leads to first-pass metabolism | | DHEA (compounded) | 25-100 mg | Daily | Converts to testosterone and estradiol; less predictable serum testosterone |

Pellet Therapy

Pellets are rice-sized cylinders of compressed crystalline testosterone implanted subcutaneously, typically in the upper buttock or hip. Absorption is slow and relatively steady. A single insertion session typically involves 4-10 pellets, depending on body weight, activity level, and baseline testosterone. Serum levels peak within 1 month and decline over 3-6 months.

The attraction of pellets is convenience: no daily application, no weekly injection. The significant limitation is irreversibility. If a patient develops erythrocytosis or another adverse effect after insertion, the pellets cannot be removed easily. Dose adjustments require waiting for the current pellets to dissolve and re-dosing at the next insertion.

Why Clinicians Sometimes Choose Compounded

Some men need doses or concentrations not available in commercial products. A man with extreme sensitivity to alcohol-based gel carriers, or one needing a very low maintenance dose (e.g., 20 mg daily) to optimize free testosterone without overshooting total testosterone, may benefit from a compounded cream. The decision should always weigh FDA-approved options first, with compounding reserved for documented clinical need.

Clinical Evidence for Testosterone Therapy in Men

The most rigorous evidence base for testosterone therapy in older men comes from the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled, double-blind studies conducted at 12 US sites in 788 men aged 65 or older with total testosterone below 275 ng/dL and age-related symptoms. [8] The TTrials used a testosterone gel (1%) titrated to achieve levels of 500-1,000 ng/dL.

Key findings from the TTrials published in the New England Journal of Medicine in 2016:

• The Sexual Function Trial: testosterone increased sexual activity, sexual desire, and erectile function compared with placebo (P<0.001 for all three domains). [8]
• The Physical Function Trial: testosterone increased walking distance in a 6-minute walk test by 34 meters more than placebo, but did not meet the pre-specified threshold for clinical significance.
• The Vitality Trial: testosterone produced modest improvements in self-reported energy and mood, though the effect size was smaller than commonly expected.
• The Bone Trial (published separately, NEJM 2017, N=211): testosterone increased volumetric bone mineral density of the spine by 7.5% and trabecular bone score by 4.9% versus placebo. [9]

The TTrials also revealed a signal worth noting. Noncalcified coronary artery plaque volume increased more in the testosterone group than in the placebo group at 12 months. Longer-term cardiovascular data from the TRAVERSE trial (N=5,198 men, mean age 63.6 years, cardiovascular risk factors required for enrollment) published in NEJM in 2023 showed that testosterone therapy was noninferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months. [10] Atrial fibrillation and acute kidney injury rates were modestly higher in the testosterone group.

The American Urological Association 2018 guideline states: "Clinicians should inform patients of the absence of definitive long-term safety data for TRT, and that therapy has not been proven to cause or worsen cardiovascular disease." [11]

Monitoring and Safety

Starting bioidentical testosterone without structured monitoring is poor clinical practice. Standard follow-up is at 3 months post-initiation, then every 6-12 months once levels are stable.

Lab Monitoring Schedule

• Total and free testosterone: Target for most men is 400-700 ng/dL total testosterone. Levels above 1,000 ng/dL increase adverse-effect risk without added symptomatic benefit in most patients.
• Hematocrit: Testosterone stimulates erythropoiesis. Hematocrit above 54% requires dose reduction or temporary cessation. [3] Venous thromboembolism risk rises with erythrocytosis.
• PSA: Testosterone does not cause prostate cancer, but it may accelerate growth of existing occult cancer. PSA monitoring every 6-12 months is standard. A rise of more than 1.4 ng/mL above baseline within 12 months warrants urology referral.
• Estradiol: Testosterone aromatizes to estradiol. Levels above 40-50 pg/mL may cause gynecomastia, water retention, and mood changes. Aromatase inhibitors (anastrozole 0.25-0.5 mg twice weekly) are sometimes added, though their use in TRT is off-label.
• LH and FSH: Exogenous testosterone suppresses both. Monitoring confirms expected suppression and can guide decisions about fertility preservation.

Common Adverse Effects and Management

Testicular atrophy and infertility occur because LH suppression reduces intratesticular testosterone. Human chorionic gonadotropin (hCG) at 500-1,000 IU subcutaneously two to three times per week maintains testicular size and intratesticular testosterone in men on TRT who wish to preserve fertility or testicular function. [12]

Acne and oily skin affect roughly 6-10% of users. Dermatologist referral is appropriate for moderate-to-severe cases.

Sleep apnea may worsen with testosterone therapy. The mechanism is not fully established, but patients with existing sleep apnea or obesity should be screened before starting therapy.

Mood changes are uncommon at therapeutic doses. Supraphysiologic dosing carries greater risk. Mood elevation with appropriate therapy is the expected outcome in hypogonadal men.

Bioidentical BHRT vs. Standard TRT: Is There a Real Difference?

From a pharmacological standpoint, testosterone cypionate injection prescribed by a urologist and testosterone cypionate compounded by a pharmacy are the same molecule. The distinction that matters clinically is:

1. Regulatory oversight: FDA-approved products have passed manufacturing quality standards. Compounded products have not undergone the same scrutiny, and potency variability has been documented.
2. Evidence base: All the major trials (TTrials, TRAVERSE, IPASS) used FDA-approved formulations or well-characterized testosterone gels.
3. Marketing claims: Some BHRT clinics imply compounded preparations are inherently safer or more "natural." No peer-reviewed evidence supports this claim. The FDA issued a 2008 statement specifically refuting the claim that compounded BHRT is safer or more effective than approved therapies. [1]
4. Customization: Compounding offers real clinical utility when standard products do not meet a patient's specific needs. That utility should be the reason for choosing compounding, not a belief in superior safety.

The Endocrine Society's position: "The use of compounded hormones remains controversial, and claims that these preparations are safer or more effective than government-approved hormone therapy are not supported by clinical evidence." [3]

Starting Bioidentical Hormone Therapy: The Clinical Pathway

A structured pathway reduces risk and improves outcomes.

Step 1: Diagnosis

Two fasting morning testosterone levels below 300 ng/dL, drawn on separate days, combined with at least one symptom domain consistent with hypogonadism. Exclude secondary causes: prolactinoma, hemochromatosis, obesity-related suppression, opioid use, and anabolic steroid history.

Step 2: Formulation Selection

Choose based on patient preference, lifestyle, cost, and any contraindications. Men with female partners or children at home should weigh transdermal transfer risk carefully. Men prioritizing convenience over dose flexibility may explore pellets. Men who want to preserve fertility should consider Natesto or clomiphene citrate.

Step 3: Titration

Start at the lower end of approved doses. Recheck total testosterone, free testosterone, and hematocrit at 6-8 weeks after initiation. Adjust dose to achieve total testosterone in the 400-700 ng/dL range for most patients.

Step 4: Ongoing Monitoring

Follow the 3-month and 6-12 month schedule outlined above. Discontinue or reduce dose promptly if hematocrit exceeds 54%, PSA rises more than 1.4 ng/mL in 12 months, or new cardiovascular symptoms develop.

Special Populations

Men Over 65

The TTrials focused on this group. Benefits in sexual function and bone density are well-established. Cardiovascular monitoring is more important given baseline risk. The TRAVERSE trial provides reassurance on short-to-medium term MACE risk.

Men With Obesity

Obesity reduces SHBG, lowering total testosterone while free testosterone may be less affected. Some men with BMI above 35 have functional hypogonadism that responds substantially to weight loss. GLP-1 receptor agonists like semaglutide, which produce 10-15% body weight reduction in clinical trials [13], may raise total testosterone by 3-5 nmol/L in obese hypogonadal men without testosterone supplementation. Evaluating testosterone after meaningful weight loss avoids unnecessary treatment.

Men With Prior Prostate Cancer

Testosterone therapy in prostate cancer survivors was historically contraindicated. Emerging evidence, including a 2016 systematic review in European Urology (N=834 men with prior low-risk prostate cancer), suggests that carefully selected men with treated, low-risk prostate cancer who are in remission may be candidates for TRT under close urological supervision. [14] This remains an area of active clinical debate and is not yet standard practice.